RapidEye:
Regeneron Pharmaceuticals (NASDAQ:RAINEye therapy maker Eylea has acquired Oxular, a UK biotech drug developer focused on ophthalmology.
While neither company officially disclosed the deal, former Oxular CEO Mark Gaffney, who currently heads immunology drug developer Calluna Pharma, shared:
Open the Editor’s Marking Free Rulla Khalaf, the FT editor, chooses its preferred stories in this…
Markets Reel as US Tariffs Salvon Stimulus Risk Risk Report Thank you for Report Game…
By Jiaxing Li Hong Kong (Reuters) – Chinese technological shares, which have been listed on Friday,…
Zuckerberg will be sold for $ 65B for AI data center that can cover “Most Menhaten”…
The entrance to this page has been rejected because we believe that you use automation tools…
In 2024, three companies took the market cap crown Report Thank you for Report Game…
English